Oncolytic measles virus strains in the treatment of gliomas.
BACKGROUND
Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy.


OBJECTIVE
In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas.


METHODS
Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described.


CONCLUSIONS
Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
Allen
Cory
C
Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA.
Paraskevakou
Georgia
G
Liu
Chunsheng
C
Iankov
Ianko D
ID
Msaouel
Pavlos
P
Zollman
Paula
P
Myers
Rae
R
Peng
Kah Whye
KW
Russell
Stephen J
SJ
Galanis
Evanthia
E
D000818:Animals; D001932:Brain Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D005910:Glioma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008458:Measles Vaccine / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D008459:Measles virus / Q000235:genetics / Q000276:immunology*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology*
D008458:Measles Vaccine